Back to Browse Journals » Infection and Drug Resistance » Volume 5

Clinical update on linezolid in the treatment of Gram-positive bacterial infections

Authors Ager S, Gould K

Published Date June 2012 Volume 2012:5 Pages 87—102

DOI http://dx.doi.org/10.2147/IDR.S25890

Received 13 April 2012, Accepted 20 April 2012, Published 25 June 2012

Sally Ager, Kate Gould

Department of Microbiology, Newcastle upon Tyne Hospitals Trust, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK


Abstract: Gram-positive pathogens are a significant cause of morbidity and mortality in both community and health care settings. Glycopeptides have traditionally been the antibiotics of choice for multiresistant Gram-positive pathogens but there are problems with their use, including the emergence of glycopeptide-resistant strains, tissue penetration, and achieving and monitoring adequate serum levels. Newer antibiotics such as linezolid, a synthetic oxazolidinone, are available for the treatment of resistant Gram-positive bacteria. Linezolid is active against a wide range of Gram-positive bacteria and has been generally available for the treatment of Gram-positive infections since 2000. There are potential problems with linezolid use, including its bacteriostatic action and the relatively high incidence of reported adverse effects, particularly with long-term use. Long-term use may also be complicated by the development of resistance. However, linezolid has been shown to be clinically useful in the treatment of several serious infections where traditionally bacteriocidal agents have been required and many of its adverse effects are reversible on cessation. It has also been shown to be a cost-effective treatment option in several studies, with its high oral bioavailability allowing an early change from intravenous to oral formulations with consequent earlier patient discharge and lower inpatient costs.

Keywords: linezolid, oxazolidinone, multi-resistant, gram-positive, MRSA, VRE, cost-benefit

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus

William J Peppard, Anne Daniels, Lynne Fehrenbacher, Jamie Winner

Infection and Drug Resistance 2009, 2:27-40

Published Date: 8 June 2009

Update on the optimal use of voriconazole for invasive fungal infections

Asma Lat George R Thompson III

Infection and Drug Resistance 2011, 4:43-53

Published Date: 3 February 2011

Recent developments in the epidemiology and management of tuberculosis – new solutions to old problems?

Thaiss WM, Thaiss CC, Thaiss CA

Infection and Drug Resistance 2012, 5:1-8

Published Date: 9 January 2012

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia

Maselli DJ, Fernandez JF, Whong CY, Echevarria K, Nambiar AM, Anzueto A, Restrepo MI

Infection and Drug Resistance 2012, 5:43-51

Published Date: 1 February 2012

Treatment of dengue fever

Rajapakse S, Rodrigo C, Rajapakse A

Infection and Drug Resistance 2012, 5:103-112

Published Date: 23 July 2012

Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance

Chen LF, Anderson DJ, Paterson DL

Infection and Drug Resistance 2012, 5:133-141

Published Date: 24 September 2012

Prevalence of extended-spectrum beta-lactamase-producing bacteria in food

Tham J, Walder M, Melander E, Odenholt I

Infection and Drug Resistance 2012, 5:143-147

Published Date: 16 October 2012

Update on the management of chronic rhinosinusitis

Cain RB, Lal D

Infection and Drug Resistance 2013, 6:1-14

Published Date: 23 January 2013